

EAPB – Mission

The European Association of Pharma Biotechnology (EAPB) is a professional association dedicated to the advancement of biotechnology in pharmaceutical sciences, specifically as applied to medicinal drugs, industrial materials, processes, products and their associated issues.

Its members constitute specialists employed in industry, government and university laboratories, biotech companies and scientific organisations.

Participation Fees*

| | Industry | Academia |
|---|----------|----------|
| Non-members rate | 540 € | 290 € |
| EAPB members rate | 490 € | 240 € |
| Technology Slam Ticket A (1 poster, incl. 1 participant) | 190 € | |
| Technology Slam Ticket B (3 posters, incl. 2 participants) | 390 € | |

* No VAT requested according to § 4.22 UStG

Posters shall be presented by oral 5 minutes presentations and in addition by traditional poster walls.

Various opportunities are offered for sponsorship and exhibition at www.eapb.org.

The conference language is English.

More Information:

EUROPEAN ASSOCIATION OF PHARMA BIOTECHNOLOGY

Ms. Berit Renaud

Theodor-Heuss-Allee, 25

Phone: +49 69 7564 381

Fax: +49 69 7564 299

Email: eapb@eapb.org

www.eapb.org

Venue

DECHEMA e.V.
Theodor-Heuss-Allee, 25
60486 – Frankfurt am Main
www.dechema.de



Sponsors and Partners

GOLD SPONSORS



SUPPORTERS



EXHIBITOR

Stolmár & Partner
Intellectual Property

MEDIA PARTNERS



Supporting Technology Transfer Organisations



EUROPEAN ASSOCIATION OF
PHARMA BIOTECHNOLOGY

7 – 8 March 2016 · Frankfurt am Main

7th Science to Market

“Leveraging Synergies”

The annual discussion and partnering conference for experts from academia, biotechnology and pharmaceutical industry.



In cooperation with

Technologie Allianz



Welcome by the President

It is my great pleasure to invite you to the 7th “Science to Market” Conference (S2M), which will take place in Frankfurt, Germany, March 7 – 8, 2016. The overall theme of the conference is: “Leveraging Synergies”.

In a plenary session the implications of Big Data will be discussed, how they are changing early steps of the discovery landscape and which role they play in drug development. A further session is dealing with the final steps of biopharma development: the regulatory environment. These inspiring plenary sessions will be complemented by the traditional and well-proven format of our tech-transfer sessions. Poster exhibitions will be accompanied by oral presentations.

We would be very happy to welcome you at the conference either as a presenter of your recent findings or as an interested project partner looking for new developments.

Wieland Wolf
EAPB President



Welcome by the Chairman of the TechnologieAllianz

We, the German association of patent marketing and technology transfer agencies, welcome you to the “Science to Market”-event. We are glad to present you a platform for discussing licensing opportunities developed at German universities and research institutes. The event is an ideal combination of outstanding sessions highlighting current biotech-/pharma trends and tech-transfer sessions offering matching inventions from academia for industry.

Thus, we invite you to two days of intensive and inspiring talks and discussions.

Alfred Schillert
Chairman of TechnologieAllianz

PROGRAMME MONDAY, 7 MARCH 2016

| | |
|--|--|
| 09:00 | Registration |
| 10:00 | Welcome, introduction & opening remarks Wieland W. Wolf, President of the EAPB |
| Session: Market Trends (Moderator: Wieland Wolf) | |
| 10:15 | Commercial Deal Structures and Recent Trends Christi Mitchell, Highbury Ltd, Hitchin, UK |
| 10:45 | Personalized medicine – are there also approaches outside Oncology? Jochen Maas, Sanofi-Aventis Deutschland GmbH, Frankfurt |
| 11:15 | Accelerating Innovation through collaboration Cord Dohrmann, Evotec AG, Hamburg |
| 11:45 | PANEL DISCUSSION |
| 12:15 | Technology Slam Session 1 (Moderator: Marion Michaelis-Kronabel) |
| 12:45 | LUNCH BREAK |
| Session: Regulatory (Moderator: Axel Wenzel) | |
| 14:00 | Medicines, medical devices and other healthcare products – differing regulatory systems Axel F. Wenzel, PSS.T, München |
| 14:30 | Challenges in the demarcation of material medical devices from medicinal products. Differences between legal and scientific assessment Peter von Czettritz, Preu Bohlig & Partner, München |
| 15:00 | Towards greater Data Transparency – Trends and Impact on Market Access in Europe Alexander Natz, EUCOPE, Brussels, Belgium |
| 15:30 | Current and upcoming regulatory requirements for In-vitro Diagnostics in EU Dieter Schönwald, TÜV SÜD Product Service GmbH, München |
| 16:00 | PANEL DISCUSSION |
| 16:30 | Coffee break |
| 17:00 | Technology Slam Session 2 (Moderator: Marion Michaelis-Kronabel) |
| 18:30 | Closing remarks Wieland W. Wolf, President of the EAPB |
| Come Together / Social Event at DECHEMA Haus | |

TUESDAY, 8 MARCH 2016 PROGRAMME

| | |
|--|--|
| 9:00 | Opening Wieland W. Wolf, President of the EAPB |
| Session: Big Data (Moderator: Holger Bengs) | |
| 9:15 | Big Data in Human Genetics: Challenges and Chances for disruptive Business Models Daniela Steinberger, bio.logis Group, Frankfurt am Main |
| 9:45 | Digital Medicine: from the App to Big Data Dr. Claus Kusnierz-Glaz, PricewaterhouseCoopers, Frankfurt |
| 10:15 | Coffee break |
| 10:45 | Genetalk- an approach to end the diagnostic odyssey for patients with rare genetic disorders Peter Krawitz, Institut für Medizinische Genetik der Charité – Universitätsmedizin Berlin |
| 11:15 | Big Data: Big Business – Big Failures? Martin Pöhlchen, Sinfonie Life Science Management GmbH, Planegg |
| 11:45 | PANEL DISCUSSION |
| 12:15 | Lunch break |
| Session: Technology Transfer (Moderator: Jürgen Walkenhorst) | |
| 13:30 | Science-to-Commercialization – a Max Planck Model for Early Innovative Drug Discovery Bert Klebl, Lead Discovery Center GmbH, Dortmund |
| 14:00 | The Infinite Value-Inflection Point: Making the Untransactable Transactable Iain Thomas, Cambridge Enterprise, Cambridge, UK |
| 14:30 | Hands on Translation: From Infinity to Beyond Michael Dalrymple, MRC Technology, London, UK |
| 15:00 | PANEL DISCUSSION |
| 15:30 | EAPB AWARD |
| 15:45 | Closing remarks Wieland W. Wolf, President of the EAPB |